Archives: Agenda

• Working closely with FSP vendors: how much oversight do you need?
• Benefits and challenges of moving to an FSP outsourcing model
• Comparing vendor management strategies between pharma and biotechs: do you need a different approach?
• Why is FSP becoming a popular outsourcing model: what benefits can this offer sponsors?

Moderator: Amanda Murphy, Senior Director, Data Intelligence & Solutions, GlobalData

• Setting up for success with large CROs in terms of contract structures, financial terms and governance from a small biotech perspective
• Implementing a gold standard strategic partnership to avoid common pitfalls and improve vendor selection
• Knowing when to outsource and detailing key activities to be performed for each vendor service to ensure proper oversight
• Factoring in necessary contracts and approvals for vendor selection in study timelines

Moderator: Robert Loll, SVP, Business Development & Strategic Planning, Praxis

• Determining team bandwidth
• Assessing clinical trial needs
• Shopping for the right CRO(s)
• Lessons learned from outsourcing

• Predict high-performing sites and investigators to accelerate enrolment
• Forecast site activation timelines with greater accuracy
• Anticipate post-marketing commitments earlier in the process
• Enhance TMF compliance and quality through intelligent automation
• Accelerate and streamline site contracting for faster study start-up
• Drive operational efficiency and cost savings through robotic process automation

• Introduction of company
• Introduction of ingredient collagen and bioactive collagen peptides
• Collagen in beverages opportunities
• Technical feasibility in beverages
• New product teaser

• Where are we with the low alcohol descriptors? What are these and why shouldn’t we use them on soft drinks?
• The importance of ‘lower’ options in the growth of low and no.
• What is mid-strength? Is this the right time to introduce a new descriptor or is this just another way to say ‘lower’?
• What’s next for the low and no sector?